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ABSTRACT 38 
 39 
Purpose: To report clinical efficacy, predictors of success and safety of primary selective laser trabeculoplasty (SLT) used in 40 
treatment-naïve open-angle glaucoma (OAG) or ocular hypertension (OHT) patients. 41 
 42 
Design: Post-hoc analysis of a multicentre prospective randomized-controlled-trial. 43 
 44 
Participants: Treatment-naïve OAG or OHT patients. 45 
 46 
Methods: Patients randomized to SLT or topical medication and treated to pre-defined target IOPs requiring ≥20% IOP reduction 47 
from baseline for all disease severity levels. 48 
 49 
Outcome Measures: Initial (“early”) absolute IOP-lowering at 2-months. Achievement of “drop-free disease-control”: meeting 50 
target IOP without disease progression or need for additional topical medication over 36-months following SLT. Predictors of 51 
early absolute IOP-lowering and drop-free “disease-control” after single initial SLT. Frequency of laser-related complications. 52 
 53 
Results:  611 eyes (195 OHT & 416 OAG) of 355 patients received SLT and 622 eyes (185 OHT & 437 OAG) of 362 patients 54 
received topical medication at baseline. Early absolute IOP-lowering following SLT was no different between OHT and OAG eyes 55 
(adjusted mean difference = -0.05mmHg; 95% confidence interval (CI) -0.6 to 0.5mmHg; p=0.85). No difference was noted in 56 
early absolute IOP-lowering between topical medication and primary SLT (adjusted mean difference = -0.1mmHg; 95% CI, -0.6 to 57 
0.4mmHg; p=0.67). Early absolute IOP-lowering with primary SLT was positively associated with baseline IOP (Coefficient 0.59; 58 
95% CI, 0.54 to 0.64; p<0.001) and negatively with female gender (Coefficient -0.63; 95% CI, -1.23 to -0.02; p=0.04). At 36-59 
months, 536 eyes (87.7% of 611 eyes) of 314 patients (88.5% of 355 patients) were available for analysis. 74.6% of eyes (400 60 
eyes) treated with primary SLT achieved drop-free “disease-control” at 36-months; 58.2% (312 eyes) following single SLT. Total 61 
SLT power and 2-month IOP were predictors of drop-free “disease-control” at 36-months following single SLT. 6 eyes of 6 62 
patients experienced immediate post-laser IOP spike (>5mmHg from pre-treatment IOP) with 1 eye requiring treatment.  63 
 64 
Conclusion: Primary SLT achieved comparable early absolute IOP-lowering in OHT vs OAG eyes. Drop-free “disease-control” was 65 
achieved in ~75% eyes at 36-months following 1 or 2 SLTs; the majority of these following single SLT. These analyses are 66 
exploratory, but support primary SLT to be effective and safe in treatment-naïve OAG and OHT eyes.  67 
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INTRODUCTION 68 
Over the past two decades, selective laser trabeculoplasty (SLT) has become an established treatment to lower IOP for primary 69 
open angle glaucoma (POAG) and ocular hypertension (OHT). Introduced by Latina and Park in 1995, SLT uses a 532nm Q 70 
switched, frequency-doubled Nd:YAG laser that delivers a short pulse duration (3 nanoseconds) (1) to reduce IOP by increasing 71 
aqueous outflow through the trabecular meshwork (TM) (2). The procedure is short and outpatient-based, with quick recovery 72 
and good safety profile (3). SLT has the potential advantage of avoiding issues associated with topical IOP lowering medications 73 
such as local and systemic side effects and variable patient adherence. Since FDA approval in 2001, SLT increasingly has been 74 
adopted into practice. In the USA, 75,647 trabeculoplasties were performed in 2001 and this increased to 142,682 procedures in 75 
2012 (4). 76 
 77 
Studies investigating SLT as a primary treatment have found a similar IOP lowering efficacy and success rate to topical 78 
medication using various success criteria (3). However, several of these studies include patients taking IOP lowering topical 79 
medications that were stopped for a variable duration prior to receiving SLT (5-8). Despite a washout period to mitigate against 80 
residual effects of prior topical treatment, SLT can be less effective following topical treatment (6). Few studies have evaluated 81 
primary SLT in true treatment-naïve patients (9-11) and there is limited knowledge of predictors of IOP lowering response, 82 
treatment success and safety in such patients. 83 
 84 
The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial was a multi-centre randomized controlled trial (RCT) conducted to 85 
establish whether initial treatment with SLT is superior to initial treatment with medication for treatment-naive OAG or OHT 86 
patients in relation to health-related quality of life (HRQL), cost-effectiveness and clinical efficacy at 36 months (12). Eyes in the 87 
primary SLT arm were at target IOP over more clinical visits during 36-month follow up compared to drops, with fewer eyes 88 
demonstrating disease progression and fewer cataract and trabeculectomy surgeries. Primary SLT was found to be more cost-89 
effective than initial medication over the course of 36 months, despite a lack of HRQL differences between the two arms (13). 90 
 91 
This report characterizes the IOP lowering, drop-free “disease-control” and safety achieved by primary SLT in treatment-naïve 92 
OAG and OHT patients as part of LiGHT, in which eyes were treated to pre-defined target IOPs based on disease severity. We 93 
also investigated predictors of initial (“early”) IOP lowering and predictors for achieving drop-free “disease-control” at 36 94 
months following single initial SLT. We hypothesized that primary SLT would demonstrate effective IOP lowering in treatment-95 
naive OHT and OAG eyes with a comparable effect to topical medication. We anticipated that absolute IOP lowering could be 96 
greater in OHT vs OAG eyes due to higher pre-treatment baseline IOPs and that drop-free “disease-control” would be more 97 
readily achieved in eyes with less advanced disease because target IOPs were higher. 98 
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METHODS 99 
The study was conducted in accordance to good clinical practice (GCP) guidelines and adhered to the tenets of the Declaration 100 
of Helsinki. Institutional Review Board (IRB)/Ethics Committee approval was obtained. All patients provided written informed 101 
consent before participation to the trial. The LiGHT Trial is registered at www.controlled-trials.com (registration number 102 
ISRCTN32038223). 103 
 104 
This study was a post hoc analysis of the LiGHT trial, the design and baseline characteristics of which have been previously 105 
described (12, 14). Briefly, consecutive eligible patients were identified at the clinics of six participating centres in the UK from 106 
October 2012 until October 2014. Eligible patients had newly diagnosed, untreated OAG or OHT in one or both eyes and 107 
qualified for treatment according to National Institute of Clinical Excellence (NICE) guidelines (15), open angles on gonioscopy, 108 
visual field loss with mean deviation (VF MD) not worse than -12 dB in the better eye or -15 dB in the worse eye and, for OAG, 109 
corresponding damage to the optic nerve head. Patients were 18 years or older and able to read and understand English, had a 110 
visual acuity of 20/120 or better in the treated eye(s) and no previous intraocular surgery, except uncomplicated 111 
phacoemulsification at least one year before entering the trial. Patients were excluded if there were any contra-indications to 112 
SLT, if they were unable to use topical medical therapy, if they had visually symptomatic cataract and wanted to undergo 113 
cataract surgery, or were having active treatment for another ophthalmic condition. Patients with one or both eyes eligible were 114 
treated. All measurements influencing treatment escalation decisions: automated visual field using Humphrey Field Analyzer 115 
Mark II Swedish interactive threshold algorithm standard 24-2 programme (Carl Zeiss Meditec, Dublin, CA, USA), Heidelberg 116 
Retina Tomography (HRT) disc imaging (Heidelberg Engineering, Heidelberg, Germany) and IOP (Goldmann applanation 117 
tonometry with daily calibration verification) were performed by masked observers. Patients were monitored for 3 years.  118 
 119 
 120 
Disease category and severity were defined using pre-set objective severity criteria from the Canadian Target IOP Workshop (16) 121 
with additional central VF loss criteria (17) – see Table 1.  122 
 123 
Severity stratification (OHT, ‘mild’, ‘moderate’ or ‘severe’ OAG) determined an eye specific 'Target IOP' and follow-up intervals. 124 
Target IOP was objectively defined using both percentage reduction from untreated IOP and an absolute value, with the final 125 
target IOP being the lower of the 2 values (see Table 2). Achievement of target IOP thus required a minimum IOP reduction of 126 
>20% from baseline IOP, irrespective of disease severity. 127 
 128 
Standardised criteria to escalate treatment were used according to a protocol following international guidelines by the 129 
European Glaucoma Society, (18) American Academy of Ophthalmology Preferred Practice Pattern (19) and the South-East Asia 130 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6
Glaucoma Interest Group (20). These were incorporated into a real-time web-based clinical decision support software, based on 131 
optic disc analysis (HRT), automated visual fields analysis (Humphrey Visual Field, HVF) and IOP measurements. Criteria for 132 
defining IOP not at target and disease progression by HRT and VF have been reported previously (12).  133 
 134 
Standardisation of SLT delivery was achieved by protocol-defined settings and clinical endpoints. The protocol advised 360-135 
degree TM treatment, 100 non-overlapping shots (25 per quadrant) of a pre-set 3 nanoseconds duration and pre-set 400μm 136 
spot size, with the laser energy varied from 0.3 to 1.9mJ by the clinician according to just observable bubble formation. IOP was 137 
checked 60 minutes following SLT procedure. One SLT re-treatment was permitted during the study, if/when a treatment 138 
escalation was recommended by the decision support software and confirmed by the treating clinician. To allow time for the full 139 
effects of laser to occur, the earliest interval at which repeat SLT was permitted was following the first scheduled visit 2 months 140 
post initial SLT. SLT was not repeated if significant complications of laser treatment occurred, if there was a lack of IOP lowering 141 
response following initial SLT (judged by the treating clinician – not protocol defined) or other new medical conditions 142 
prevented repetition. In such cases, treatment escalation with topical medication rather than repeat SLT was permitted. In eyes 143 
that underwent repeat SLT, if further treatment escalation was required, the next step was topical medication. The earliest 144 
planned interval at which this could be initiated was following the first scheduled visit 2 months post repeat SLT. 145 
 146 
Follow-up intervals were initially set at entry to the study according to NICE guidance (21) and subsequently adjusted on the 147 
basis of IOP control, glaucoma progression or adverse reactions. The routine schedule of appointments and assessments for 148 
patients has been published previously (14). At follow up, patients underwent visual acuity testing (ETDRS logMAR), slit-lamp 149 
examination, visual field testing (Humphrey Field Analyzer (HFA) Mark II SITA standard 24-2), HRT optic disc imaging, IOP 150 
measurement (Goldmann applanation tonometry) and clinical assessment of the optic discs, maculae and fundi. 151 
 152 
To investigate the IOP lowering efficacy of primary SLT for OHT vs OAG, we evaluated the initial (“early”) absolute IOP reduction 153 
at 2-months for all eyes receiving primary SLT. This was the first scheduled visit (after ‘safety’ IOP check visit at 2 weeks post 154 
laser) following laser at baseline. To contextualize the early IOP lowering efficacy of primary SLT in treatment-naïve eyes, we 155 
compared early absolute IOP reduction at 2-months following primary SLT with 2-month absolute IOP reduction in eyes from the 156 
Medication-1
st
 arm of LiGHT that had commenced topical medication at baseline. To investigate if early absolute IOP lowering 157 
following primary SLT was predicted by clinically relevant baseline factors, a linear regression analysis was performed (see 158 
Statistical Methods). 159 
 160 
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LiGHT followed a ‘Treat in Pursuit of Control' design (TPC) and hence, following the first scheduled visit at 2-months, the web-161 
based clinical decision support software began to monitor and escalate treatment (if required) for each eye based on 162 
achievement of “disease-control” i.e. achievement of predefined target IOP with no objective evidence of disease progression. 163 
OAG eyes had lower predefined target IOPs than OHT eyes (see Table 2) and thus were more likely to require greater treatment 164 
intensity compared to OHT eyes to achieve “disease-control”. IOP comparisons between OHT vs OAG eyes at later time points 165 
would be confounded by differences in treatment intensity and hence were not performed.  166 
 167 
We evaluated treatment intensity of primary SLT in OHT vs OAG eyes by assessment of drop-free “disease-control” achieved by 168 
primary SLT at 12, 24 and 36 months. The LiGHT treatment protocol permitted a single SLT retreatment (if required) and we 169 
therefore determined drop-free “disease-control” achieved by 1 or 2 SLTs collectively and by initial, single SLT alone.  170 
In the SLT literature, the most commonly defined measure of ‘success’ is a minimum IOP reduction of ≥ 20% from baseline IOP 171 
following SLT at a specified time point, without need for further intervention (22). In LiGHT, the predefined target IOPs required 172 
a minimum IOP reduction of > 20% from baseline IOP for all disease severities (see Table 2) and thus, eyes achieving drop-free 173 
“disease-control” at 36 months following a single, initial SLT would serve as a useful (albeit much more stringent) ‘success’ 174 
comparator with pre-existing SLT studies. A logistic regression analysis of factors to predict eyes achieving drop-free “disease-175 
control” at 36 months following initial, single SLT was performed. 176 
To determine safety of primary SLT, the frequency of laser related complications and adverse events over 36 months was 177 
collated. 178 
STATISTICAL METHODS 179 
The sample size for LiGHT was based on analyses planned to assess HRQL in treatment-naïve OAG/OHT patients treated initially 180 
with either primary SLT or topical medication. The sample size was 718 patients, calculated to detect a difference of 0.05 in EQ-181 
5D-5L between the two arms at 36 months using a two sample t-test at the 5% significance level with 90% power, assuming a 182 
common standard deviation of 0.19 (23) and 15% attrition. 183 
In this report, the unit of analysis was the eye. All eligible study eyes that received SLT at baseline were included in the analysis 184 
with appropriate measures taken to account for correlation amongst paired eyes within a subject.  185 
Summary statistics of the demographic and clinical characteristics are presented for all eligible study eyes. Descriptive statistics 186 
are presented as means and standard deviations. Analysis comparing baseline demographics of eyes available to those 187 
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unavailable to analyze at 36-months was performed. T-test or Wilcoxon Rank Sum test was used for comparison of continuous 188 
data and Chi squared test was used for categorical data.  189 
 190 
To compare absolute IOP reduction at 2 months between OHT and OAG eyes, a mixed effects model using the eye as the unit of 191 
analysis and using patients as a random factor to adjust for correlation between paired eyes was performed. The model also 192 
controlled for pre-treatment baseline IOP and treating centre (to control for centre effects in a multicentre trial). To compare 193 
absolute IOP reduction at 2 months between primary SLT vs topical medication, a similar mixed effects model was also used. 194 
 195 
To examine baseline predictors of early absolute IOP reduction at 2 months in eyes receiving primary SLT, univariate mixed 196 
effect linear regression analyses were performed using the eye as the unit of analysis and using patients as a random factor to 197 
adjust for correlation between paired eyes. Patient related baseline characteristics considered for univariable selection were 198 
age, gender, ethnicity, phakic status, baseline IOP, central corneal thickness (CCT), TM pigmentation, pseudoexfoliation (PXF), 199 
hypertension (HTN) & diabetes mellitus (DM). Laser related characteristics included total SLT power and total number of SLT 200 
shots of initial SLT at baseline. Covariates that achieved p<0.10 in the univariable selection regression analyses were entered in a 201 
mixed effect multivariable linear regression model controlling for LiGHT stratification factors (disease severity and treating 202 
centre). The regression model was then run, with non-significant variables removed one by one until only significant (p<0.05) 203 
variables remained.  204 
A similar approach involving logistic regression was used to look for predictors of drop-free “disease-control” at 36 months. For 205 
the logistic regression analysis, a ‘success’ criterion defined as eyes that achieved drop-free “disease-control” following initial, 206 
single SLT at baseline was used. This was a more stringent criterion than used elsewhere. We also considered the 2-month IOP 207 
to assess if this was a post treatment predictor of drop-free “disease-control” at 36 months. 208 
 Statistical significance was defined as a 2-sided P value <0.05. Analyses were carried out using Stata15 (StataCorp, 2015. Stata 209 
Statistical Software: Release 15. College Station, TX: StataCorp LP). 210 
  211 
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RESULTS 212 
356 patients (613 eyes) were randomized to the Laser 1
st
 arm of LiGHT. One patient (2 eyes) withdrew consent prior to receiving 213 
SLT at the baseline visit and thus 355 patients (611 eyes) received primary SLT. At 36 months, 536 eyes of 314 patients were 214 
available for analysis. Of the 75 remaining eyes, 22 eyes (of 13 patients) were formally lost to follow up (withdrew, died, illness, 215 
or moved) during the course of the 3-year trial. The remaining 53 eyes (of 28 patients) were still returning HRQL questionnaires 216 
in the main LiGHT study, but clinical data were not available at the 36-month time-point. Analysis comparing baseline 217 
demographics of eyes available vs unavailable to analyze at 36-months (536 eyes vs 77 eyes) demonstrated no clinically or 218 
statistically significant differences in age, baseline IOP, ethnicity, gender, disease severity and VF mean deviation. A statistically 219 
but not clinically significant difference in baseline visual acuity was noted between groups (mean difference LogMAR -0.06 ,95% 220 
CI, -0.1 to -0.01, p=0.02) (see Appendix: available at www.aaojournal.org).  221 
 222 
 223 
 224 
 225 
 226 
 227 
 228 
 229 
 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
 242 
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Baseline Characteristics 243 
 244 
Baseline demographic data of the 611 eyes are given in Table 3. There was a greater proportion of males compared to females 245 
(56.1% vs 43.9%) at baseline. The most common ethnicities were White European (68.2%) and Black (21.7%). 72.1% of patients 246 
had both eyes in the study, 13.8% had only the right eye and 14.1% had only the left eye in the study; 31.9% of eyes had a 247 
diagnosis of OHT (195 eyes) compared to 68.1% of eyes with OAG (416 eyes). This is reflected in the average mean deviation 248 
(MD) value of -3.0 decibels (dB). Mean baseline IOP was 24.5mmHg (SD 5.2) for all eyes but was greater in OHT eyes (26.5mmHg 249 
(SD 3.5)) vs OAG eyes (23.5mmHg (SD 5.6)). During initial SLT, mean total power delivered was 90.4 (SD 23.5) mJ via a mean 250 
treatment of 99.2 (SD 5.1) shots. Baseline demographic data of the 622 eyes in the Medication 1
st
 arm is also provided (see 251 
Appendix: available at www.aaojournal.org) 252 
 253 
 254 
Early IOP lowering efficacy of Primary SLT 255 
559 eyes (out of 611 eyes at baseline) were available for analysis at the 2-month time point in the primary SLT arm having 256 
undergone initial SLT at baseline (see Figure 1). Mean initial IOP lowering at 2 months was 8mmHg (SD 4.0) in OHT eyes and 257 
6.5mmHg (SD 4.3) in OAG eyes. Mean percentage IOP reduction was 29.7% (SD 13.1) in OHT eyes and 26.1% (SD 14.7) in OAG 258 
eyes respectively. A clear trend was noted towards increasing absolute IOP reduction with higher baseline IOP in both OHT and 259 
OAG eyes (see Figure 1) but there was no significant difference in early absolute IOP lowering between OHT and OAG eyes 260 
having controlled for pre-treatment baseline IOP and centre effects (adjusted mean difference = -0.05mmHg; 95% confidence 261 
interval (CI) -0.6 to 0.5mmHg; p=0.85). 262 
 263 
For comparison, 594 eyes (out of 622 eyes at baseline) were available for analysis in the Medication 1
st
 arm at 2 months. Of 264 
these, 99.3% (590 eyes) were on a single medication (96.1% on topical prostaglandin, 1.9% on beta blocker, 0.3% on carbonic 265 
anhydrase inhibitor, 0.3% on alpha agonist, 0.7% on two medications). Mean initial IOP lowering at 2 months was 7.6mmHg (SD 266 
4) in OHT eyes and 6.8mmHg (SD 4.4) in OAG eyes. Mean (SD) percentage IOP reduction was 27.9% (13.5) in OHT eyes and 267 
27.9% (14.4) in OAG eyes respectively. 268 
 269 
Overall, absolute IOP reduction at 2 months was no different between topical medication and primary SLT (adjusted mean 270 
difference = -0.1mmHg; CI -0.6 to 0.4mmHg; p= 0.67). There was no difference in absolute IOP reduction for OHT eyes (adjusted 271 
mean difference = 0.4mmHg; CI -0.4 to 1.2mmHg; p=0.31) or OAG eyes (adjusted mean difference = -0.2mmHg; CI -0.8 to 272 
0.3mmHg; p=0.36) between the two treatment groups. 273 
 274 
 275 
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Predictors of early IOP lowering response following Primary SLT 276 
For the predictors of initial IOP lowering response, covariates that achieved p<0.10 in the initial variable selection regression 277 
analyses were baseline IOP (p<0.001), gender (p=0.002) and age (p=0.05). Within group (OHT vs OAG) sub-analysis 278 
demonstrated that the trend noted towards increasing absolute IOP reduction with higher baseline IOP (see Figure 1) was 279 
significant in both OHT (Coefficient 0.68, 95% CI, 0.55 to 0.81; p<0.001) and OAG (Coefficient 0.58, 95% CI, 0.53 to 0.64; 280 
p<0.001). The final multivariable linear regression model showed that baseline IOP (p<0.001) and gender (p=0.04) were 281 
predictors of initial absolute IOP reduction. 282 
 283 
 284 
“Drop-free Disease-control” 285 
 286 
Eyes that met target IOP without disease progression or need for topical IOP lowering medication were deemed to have 287 
achieved drop-free “disease-control”. At 12 months, 85.2% of eyes (518 eyes) achieved drop-free ‘disease-control’ after 1 or 2 288 
SLTs. At 24 months and 36 months, 79.2% of eyes (456 eyes) and 74.6% of eyes (400 eyes) respectively, continued to achieve 289 
drop-free ‘disease-control’ (see Table 6). At all time points, drop-free ‘disease-control’ was achieved in a higher percentage of 290 
OHT and ‘mild OAG’ eyes compared to ‘moderate’ and ‘severe’ OAG eyes. 291 
 292 
 293 
‘Drop-free Disease-control’ following initial single SLT 294 
Assessing drop-free ‘disease-control’ achieved by initial single SLT at baseline, 75.5% of eyes (459 eyes) achieved this at 12 295 
months, 66.5% of eyes (383 eyes) at 24 months and 58.2% of eyes (312 eyes) at 36 months. At all time points, drop-free 296 
‘disease-control’ after single initial SLT was achieved in a higher percentage of OHT and ‘mild OAG’ eyes compared to ‘moderate’ 297 
and ‘severe’ OAG eyes (see Table 7). 298 
 299 
Overall at 36 months, mean absolute IOP reduction in the 312 eyes achieving drop-free “disease-control” following single initial 300 
SLT at baseline was 8.1mmHg (SD 4.1). Mean absolute IOP reduction was similar between all disease severities (see Table 8). 301 
 302 
By 36 months, 23 eyes had objective evidence of disease progression (19 eyes visual field progression, 2 eyes disc progression, 2 303 
eyes disc and VF progression) and 26 eyes had an upward revision of target IOP, if IOP control was not initially achieved in the 304 
absence of disease progression (12). These results accounts for this, such that all eyes achieving drop-free “disease-control” met 305 
target IOP (achieving >20% IOP reduction from baseline IOP) without disease progression or need for topical medication. This is 306 
reflected in the number of eyes achieving drop-free “disease-control” at 36 months (74.6% eyes) and following single initial SLT 307 
(58.2% eyes) being slightly fewer compared to those solely achieving target IOP without topical medication at 36 months (78.2% 308 
eyes) and following single initial SLT (59.9%) as reported in the LiGHT main outcomes paper (13). 309 
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Predictors of drop-free ‘disease-control’ at 36 months 310 
312 eyes achieved drop-free “disease-control” at 36 months following initial single SLT (Table 8). These eyes achieved >20% IOP 311 
reduction from baseline IOP and thus were a treatment ‘success’ (using conventional ‘IOP lowering >20% from baseline IOP’ 312 
definition of success). Baseline covariates that achieved p<0.10 in the mixed effects univariable logistic regression analyses 313 
were: total power of 1
st
 SLT (p=0.08) and age (p=0.09) (see Table 9).  Two month IOP (p<0.001) was a ‘post’ treatment covariate 314 
that achieved p<0.10 in the univariable logistic regression analysis. The final mixed effects multivariable logistic regression 315 
model of baseline factors showed that total power of 1
st
 SLT (see Table 10) was a predictor of achieving drop-free “disease-316 
control” at 36 months following single initial SLT (adjusted odds ratio 1.02, 95% CI, 1.01 to 1.04, p=0.01). Two month IOP was 317 
also a ‘post’ treatment predictor of drop-free ‘disease-control’ at 36 months when controlling for the other significant baseline 318 
factors (adjusted odds ratio 0.66, 95% CI, 0.57 to 0.79, p<0.001) (see Table 10). 319 
  320 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 13
SLT safety 321 
There were no sight threatening adverse events related to primary SLT during or after the procedure (see Table 11). 6 eyes (of 6 322 
patients) experienced immediate post laser IOP spike (>5mmHg from pre-treatment IOP) at 60 minutes, but only one of these 323 
eyes required medical treatment. No IOP spikes >10mmHg from pre-treatment IOP at 60 minutes post procedure were 324 
reported. In 4 patients (1.1%), there was difficulty in visualizing the angle and in 3 patients (0.9%) fewer laser applications than 325 
required by the protocol were reported to have been used. Following SLT, symptoms including ocular discomfort, headache, 326 
blurred vision and photophobia were reported by 34.4% of patients (122 patients). These were of a transient nature and self-327 
limiting; all had resolved by the first scheduled visit. No IOP spikes (>5mmHg from Baseline IOP) were detected at the 2-week 328 
safety check visit post SLT; 6.2% of eyes (38 eyes) were noted to have a higher IOP at 2-week safety visit compared to baseline.  329 
 330 
DISCUSSION 331 
This report analyses the efficacy of primary SLT in one of the largest datasets of treatment-naïve OAG and OHT patients, with 332 
robust RCT-derived data.  333 
 334 
There was no significant difference in early absolute IOP lowering between OHT and OAG eyes having controlled for pre-335 
treatment baseline IOP and centre effects (adjusted mean difference = -0.05mmHg; 95% confidence interval (CI) -0.6 to 336 
0.5mmHg; p=0.85). In addition, there was no significant difference in early absolute IOP lowering between topical medication 337 
and primary SLT (adjusted mean difference = -0.1mmHg, CI -0.6 to 0.4mmHg, p= 0.67).  338 
 339 
We found that higher baseline IOP was a predictor of early absolute IOP lowering at 2 months in a mixed effects linear 340 
regression model. Increasing baseline IOP has already been reported as being associated with increased IOP lowering (3) and 341 
was also demonstrated in this study, in which OHT eyes had greater IOP lowering from baseline compared to OAG eyes. This is 342 
also reflected in NTG studies where baseline IOPs are lower and both absolute IOP reductions and success rates are lower 343 
compared to other subtypes (24, 25). Our study design minimized the effects of regression to the mean on IOP lowering: 344 
qualifying IOP measurements were made on a separate day to baseline assessments, and IOP level was an entry criterion only 345 
for OHT eyes (31.9% of eyes at baseline). There was no placebo arm in LiGHT to ascertain fully the regression to the mean, but a 346 
previous study has demonstrated a ~ 1.4mmHg (SD 3.1) absolute IOP reduction at first visit post placebo compared to 5mmHg 347 
(SD 3.6) in the topical latanoprost group (26). We also found in our analysis that female gender was associated with lesser initial 348 
IOP lowering, not a commonly reported predictor of IOP lowering (22). 349 
 350 
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Our results show that at 36 months follow up, 74.6% of eyes (400 eyes) treated with primary SLT achieved drop-free “disease-351 
control”, with 58.2% of eyes (312 eyes) doing so following a single initial SLT. All these eyes achieved IOP reduction > 20% from 352 
baseline IOP. IOP reduction >20% from baseline has been previously reported as occurring in between 38-74% of treated eyes at 353 
36 months (7, 27-29).  In our study, eyes with more advanced glaucoma had to meet more stringent target IOPs set according to 354 
previous published guidelines: ‘moderate’ or ‘severe’ disease had to achieve a minimum 30% reduction from baseline IOP to 355 
continue without further intervention (12). Thus, more severely affected eyes achieving >20% but <30% IOP reduction following 356 
first SLT would have undergone a further treatment (2
nd
 SLT or medication if non-response to 1
st
 SLT). This is reflected in our 357 
results with only 58.2% of eyes not receiving additional therapy. The relative proportion of eyes achieving drop-free “disease-358 
control” at 36 months after initial single SLT at baseline (Table 7) was greater in OHT and ‘mild OAG’ eyes (with less stringent 359 
targets) than ‘moderate’ and ‘severe OAG’ eyes (with lower target IOPs), despite similar mean absolute IOP reductions for all 360 
levels of disease severity (Table 8). This does not mean SLT was ineffective in more advanced disease, merely insufficient in 361 
isolation. 362 
 363 
The above was taken into account in the predictors of success mixed effects logistic regression model, with terms for baseline 364 
disease severity and site (to control for centre effects), whilst using the eye as the unit of analysis and using patients as a 365 
random factor to adjust for correlation between paired eyes. Our logistic regression model suggested a statistically significant 366 
but small increase in odds of achieving drop-free “disease-control” at 36 months with higher total power of 1
st
 SLT (adjusted 367 
odds ratio 1.02, 95% CI 1.01 to 1.04, p=0.01). On further analysis, mean total power of 1
st
 SLT in ‘success’ eyes was 92.6mJ (SD 368 
21.8) vs 87.7mJ (SD 25.6) in ‘non-success’ eyes (adjusted mean difference = 2.37mJ, 95% CI -0.5, 5.2 mJ). The modest effect and 369 
overlap in treatment parameters between ‘success’ and ‘non-success’ eyes means that response prediction is not possible. The 370 
trend to a greater response with more power delivered would need confirmation in future studies. There is mixed evidence 371 
regarding the optimum power settings for SLT treatment. Tang et al compared 39 patients receiving 100 shots of 360
0
 SLT using 372 
low energy settings (0.3-0.5mJ) with 35 patients who received 100 shots of 360
0
 SLT using standard energy settings (0.6-1.0mJ) 373 
(30). No difference in IOP lowering between groups at all time points up to 1 year was noted. Furthermore, there was reduced 374 
incidence of adverse events in the lower energy group. Realini found total laser power not to be a significant predictor of 12-375 
month success, with a mean (SD) of 86.0 (21.1) mJ in right eye and 87.7 (20.6) mJ in left (31) compared to a mean (SD) of 90.4 376 
(23.5) mJ in our study (8). In contrast, Lee et al found greater total SLT energy was associated with a greater IOP lowering, but 377 
that study was limited by small sample size, short follow up (1 month) (32) and total energy powers that were considerably 378 
higher than those in this study (“optimum” total reported as 226.1mJ). Habib et al divided 360 degree SLT treatment patients 379 
into those who received low (<85 mJ), medium (85–105 mJ), or high (>105 mJ) energy SLT. At all time points up to 36-month 380 
follow-up, there was a significant positive correlation between greater energy and IOP lowering (33).  381 
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 382 
We wanted to establish whether IOP at first scheduled visit post SLT at 2 months was predictive of achieving “disease-control” at 383 
36 months following initial single SLT at baseline. A previous study found that the only significant predictor of IOP lowering at 12 384 
months across all eyes was time, with maximum IOP reduction seen at 3 months followed by a slow decline in effect 385 
subsequently (31). Whilst we found successful eyes achieving drop-free “disease-control” following initial single SLT at 36 386 
months had a lower IOP at 2 months compared to non-successful eyes (adjusted mean difference = -1.9mmHg; 95% CI, -1.4 to -387 
2.3mmHg), there may not be enough specificity in this observation (due to the standard deviation of IOP measurements) to be 388 
helpful in the individual case. 389 
 390 
SLT was well tolerated in this study, with no sight threatening adverse events and only 6 eyes (1% of total eyes receiving SLT) 391 
having an IOP spike (>5mmHg) immediately after SLT. This compares favorably with other studies, which have reported IOP 392 
spikes (>5mmHg) occurring in up to 28% of eyes (3). Post SLT, 34.4% of patients described mild laser related adverse events 393 
including ocular discomfort, headache, blurred vision and photophobia. These were of a transient nature and self-limiting. 394 
Anterior chamber inflammation is common post SLT with up to 83% of eyes demonstrating some degree of inflammation (34). 395 
Considering the biological changes that SLT induces (35), some regard transient self-limiting inflammation to be a predictable 396 
consequence of SLT, explaining the symptoms of ocular redness, photophobia and pain that patients may report. During the 397 
LiGHT trial overall, there were fewer drop-related ophthalmic and systemic adverse events reported by patients in the initial SLT 398 
arm vs the initial Medication arm(13). 399 
 400 
Direct comparison between SLT studies is difficult. Differences in study design exist between studies, including patient 401 
demographics, disease subtypes investigated (OHT vs OAG), variations in topical IOP lowering medication usage prior to SLT 402 
(treatment-naïve vs medication washout period prior to SLT vs adjunct SLT in uncontrolled eyes on maximum tolerated medical 403 
therapy), differences in SLT treatment parameters (180-degree vs 360-degree treatments, variability in numbers of shots fired), 404 
variability in follow up intervals, total duration of follow up and variable definitions of success.  405 
 406 
This report has several strengths. It utilizes data derived from a prospective multi-centre RCT with broad entry criteria that 407 
maximize its generalizability. Eyes were treated to pre-defined target IOPs based on disease severity with pre-defined treatment 408 
escalation criteria and SLT treatment parameters (12). An obvious limitation is that this analysis was post-hoc and the sample 409 
size of LiGHT was determined based on a power calculation to analyze the primary outcome of HRQL. We did not perform a 410 
post-hoc power calculation for the IOP lowering parameters considered in this report, since limitations have been reported with 411 
such calculations (36). Instead, the narrow (<1mmHg) confidence intervals for our pointwise estimates of differences in early IOP 412 
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lowering between OHT vs OAG eyes and primary SLT vs topical medication suggest that the study had an adequate sample size 413 
to detect a clinically important difference if it exists (37). For our logistic regression analysis, we had sufficient events based on 414 
the rule of thumb that 10-15 ‘events per variable’ are required to develop an adequate prediction model (38). In this analysis, 415 
despite no clinically or statistically significant differences in gender or ethnicity being noted in eyes available vs unavailable to 416 
analyze at 36-months, relatively more females and black patients had eyes unavailable for analysis. Studies have shown 417 
disparities in the utilization of eye care services among different racial minorities, with socio-economic deprivation and 418 
differences in access to healthcare implicated as contributory to this (39, 40).  419 
 420 
In conclusion, we report that primary SLT is an effective initial therapy for treatment-naive OAG and OHT patients. Primary SLT 421 
provides a comparable initial IOP lowering response in OHT vs OAG eyes and to topical medication. It achieves drop-free 422 
“disease-control” in ~75% of eyes at 36 months, with the majority of eyes (58.2%) doing so following a single, initial SLT. SLT had 423 
a good safety profile during our study, whilst avoiding the potential adherence issues associated with topical medication. 424 
Despite the exploratory nature of these analyses, our results are clinically valuable and add to the limited body of evidence on 425 
primary SLT in treatment-naïve OAG and OHT, supporting its’ use as an effective and safe initial treatment for such conditions. 426 
  427 
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LEGENDS: 529 
 530 
Figure 1: Scatter plot of absolute IOP reduction vs. baseline IOP in all eyes (559 eyes) at 2 months following initial SLT 531 
 Filled circles: OHT, Hollow circles: OAG 532 
 533 
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Severity Definition of Severity for Treatment Target IOP 
  Optic Nerve   VF MD   Central (10
o
) Scotoma on VF 
OHT Healthy   Any   No GON related VFL 
Mild OAG GON + > -6dB + None 
Moderate 
OAG 
GON + 
-6dB < and < -
12dB 
or 
 
 
At least 1 central 5º point <15dB 
but none <0dB and only 1 
hemifield with central point 
<15dB 
Severe 
OAG 
GON + < -12dB or 
 
 
 
Any central 5º point with 
sensitivity <0dB 
Both hemifields contain point(s) 
<15dB within 5º of fixation 
Table 1: Severity criteria for setting Treatment Target IOP from the “Canadian Target IOP Workshop” (with central field 
criteria defined according to Mills). VF MD: Visual field mean deviation GON: Glaucoma optic neuropathy 
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Baseline Disease Severity Treatment Target IOP 
OHT >20% IOP reduction from baseline IOP or IOP< 25mmHg (whichever lower) 
‘Mild’ OAG >20% IOP reduction from baseline IOP or IOP< 21mmHg (whichever lower) 
‘Moderate’ OAG >30% IOP reduction from baseline IOP or IOP<18mmHg (whichever lower) 
‘Severe’ OAG >30% IOP reduction from baseline IOP or IOP<15mmHg (whichever lower) 
 
Table 2: Setting Treatment Target IOP 
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Characteristics Value 
Age (years), mean (SD) 63.4 (12.1) 
Gender (patients), (%) 
Male 
Female 
 
199 (56.1%) 
156 (43.9%) 
Race/ Ethnicity (patients), (%) 
White European  
Black 
Asian 
Other  
 
242 (68.2%) 
77 (21.7%) 
23 (6.5%) 
13 (3.7%) 
Laterality (patients), (%) 
Bilateral Eyes 
Right Eye 
Left Eye 
 
256 (72.1%) 
49 (13.8%) 
50 (14.1%) 
Hypertension (patients), (%) 
Yes 
No 
 
131 (36.9%) 
224 (63.1%) 
Diabetes Mellitus (patients), (%) 
Yes 
No 
 
41 (11.6%) 
314 (88.5%) 
Disease Severity (eyes), (%) 
OHT 
‘Mild’ OAG 
‘Moderate’ OAG 
‘Severe’ OAG 
 
195 (31.9%) 
309 (50.6%) 
67 (11.0%) 
40 (6.5%) 
Mean Deviation (dB), mean (SD) -3.0 (3.4) 
Pattern Standard Deviation (dB), mean (SD) 3.7 (2.9) 
Mean HRT area (mm2), mean (SD) 1.2 (0.4) 
Baseline IOP (mmHg), mean (SD) 
Overall 
OHT 
OAG 
 
24.5 (5.2) 
26.5 (3.5) 
23.5 (5.6) 
Average Trabecular Pigmentation Grade (eyes), (%) 
0 -None 
1- Mild 
2-Moderate 
3-Dense 
Unknown 
 
243 (39.8%) 
264 (43.2%) 
101 (16.5%) 
1 (0.2%) 
2 (0.4%) 
Habitual VA (Logmar), mean (SD) 0.10 (0.2) 
CCT (microns), mean (SD) 550.6 (38.1) 
PXF (eyes), (%) 
Yes 
No 
 
5 (0.8%)  
606 (99.2%) 
Target IOP (mmHg) 
OHT 
‘Mild’ OAG 
‘Moderate’ OAG 
‘Severe’ OAG 
 
21.1 (2.4) 
17.9 (3.1) 
15.9 (2.6) 
13.9 (1.6) 
 
 
Table 3: Baseline characteristics of Primary SLT arm. OAG: Open Angle Glaucoma, OHT: Ocular Hypertension. Self-defined 
ethnicity; ‘Asian’ ethnicity refers to Indian, Pakistani, Bangladeshi and any other Asian background, ‘Black’ ethnicity refers 
to Caribbean, African and any other black background, ‘Other’ ethnicity refers to Chinese and any other ethnic groups. 
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Variable Coefficient 95% confidence 
Interval 
P-value 
Baseline IOP 
(mmHg) 
0.59 
 
(0.54, 0.64) <0.001* 
Race/ Ethnicity 
Black 
Asian 
Other 
*reference White European 
 
1.18 
0.89 
0.70 
 
 (0.08, 2.29) 
(-0.87, 2.66) 
(-1.75, 3.15) 
 
0.17 
Sex 
Female 
 
-1.42 
 
(-2.29, -0.54) 
 
0.002* 
Age 
(years) 
-0.04 (-0.08, 0.00) 0.05* 
CCT 
(microns) 
0.01 (0.00, 0.02) 0.15 
PXF (Y/N) 
No 
 
-1.62 
 
(-4.94, 1.69) 
 
0.34 
Average TM Pigmentation Grade 
1- Mild 
2-Moderate 
3-Dense 
*reference No Pigmentation 
 
-0.12 
0.03 
6.51 
 
(-1.04, 0.81) 
(-1.16, 1.23) 
(1.06, 12.0) 
0.12 
Phakic Status (Y/N) 
Phakic 
 
0.70 
 
(-0.90, 2.29) 
 
0.39 
Hypertension (Y/N) 
No 
 
0.05 
 
(-0.87, 0.96) 
 
0.92 
Diabetes Mellitus (Y/N) 
No 
 
0.82 
 
(-0.51, 2.15) 
 
0.22 
Total Power 1
st
 SLT 
(mJ) 
0.01 (-0.01, 0.03) 0.29 
Total Number of shots 1
st
 SLT 
(shots) 
0.04 (-0.03, 0.11) 0.26 
 
 
Table 4: Univariable Linear Regression Analysis for Absolute IOP Reduction 
*Covariates that achieved p<0.10 in the initial variable selection linear regression analyses were: baseline IOP (p<0.001), 
gender (p=0.002) and age (p=0.05) 
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Variable Coefficient 95% confidence 
Interval 
P-value 
Baseline IOP 
(mmHg) 
0.58 (0.53, 0.63) <0.001 
Sex 
Female 
 
-0.63 
 
(-1.23, -0.02) 
 
0.04 
Table 5: Multivariable Logistic Regression Analysis for Absolute IOP reduction 
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Table 6: Eyes achieving drop-free “disease-control” using 1 or 2 SLT. a: one eye was protocol deviation - received 3 SLT   
 
Disease Severity 
 
12 months 
Total eyes 
available for 
analysis 
(n) 
12 months 
Eyes achieving 
drop-free 
‘disease-control’ 
% (n) 
 
24 months 
Total eyes 
available for 
analysis 
(n) 
24 months 
Eyes achieving 
drop-free 
‘disease-
control’% (n) 
 
36 months 
Total eyes 
available for 
analysis 
(n) 
36 months 
Eyes achieving 
drop-free 
‘disease-
control’% (n) 
 
ALL EYES 608 85.2% (518) 576 79.2% (456) 536 74.6% (400)
a
 
 
OHT 192 92.7% (178) 174 92% (160) 158 88.6% (140) 
‘Mild’ OAG 315 87.3% (275) 293 81.2% (238) 269 76.6% (206) 
‘Moderate’ OAG 54 63% (34) 69 56.5% (39) 57 56.1% (32) 
‘Severe’ OAG 47 65.9% (31) 40 47.5% (19) 52 42.3% (22) 
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Table 7: Eyes achieving drop-free ‘disease-control’ after single, initial SLT at baseline 
 
Disease Severity 12 months 
Total eyes 
available 
for analysis 
(n) 
 
12 months 
Eyes achieving 
drop-free 
‘disease-control’ 
after single SLT 
% (n) 
24 months 
Total eyes 
available for 
analysis 
(n) 
 
24 months 
Eyes achieving 
drop-free 
‘disease-control’ 
after single SLT 
 
% (n) 
 
36 months 
Total eyes 
available for 
analysis 
(n) 
 
36 months 
Eyes achieving  
drop-free ‘disease-
control’  
after single SLT 
 
% (n) 
 
ALL EYES 608 75.5% (459) 576 66.5% (383) 536 58.2% (312) 
 
OHT 192 85.9% (165) 174 80.5% (140) 158 72.8% (115) 
‘Mild’ OAG 315 79.4% (250) 293 70.6% (207) 269 64.3% (173) 
‘Moderate’ OAG 54 46.3% (25) 69 42% (29) 57 33.3% (19) 
‘Severe’ OAG 47 40.4% (19) 40 17.5% (7) 52 9.6% (5) 
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Drop-free  
‘disease-control’ 
using single SLT at 
36 months 
(eyes) 
Mean(SD) 
absolute IOP 
reduction 
(mmHg)  
Mean (SD) % IOP 
reduction from 
baseline 
ALL EYES 312 8.1 (4.1) 31.4 (11.7) 
 
OHT 115 8.8 (3.6) 32.7 (11.5) 
‘Mild’ OAG 173 7.5 (4.3) 29.9 (11.7) 
‘Moderate’ OAG 19 8.6 (3.9) 36.4 (11.7)) 
‘Severe’ OAG 5 8.2 (4.6) 34.4 (13.1) 
 
Table 8: Mean IOP reduction and Percentage IOP reduction at 36 months in eyes achieving drop-free “disease-control” 
after single initial SLT 
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Variable Odds Ratio 95% confidence 
Interval 
P-value 
Baseline IOP 
(mmHg) 
1.01 
 
(0.95, 1.09) 0.69 
Race/ Ethnicity 
Black 
Asian 
Other 
*reference White European 
 
1.55 
0.74 
1.78 
 
 (0.57, 4.20) 
(0.16, 3.41) 
(0.23, 13.64) 
 
0.74 
Sex 
Female 
 
0.57 
 
(0.26, 1.28) 
 
0.17 
Age 
(years) 
0.97 (0.94, 1.00) 0.09* 
CCT 
(microns) 
1.00 (0.99, 1.01) 0.62 
PXF Status 
Nil PXF 
 
18.9 
 
(0.28, 1294.66) 
 
0.17 
Average TM Pigmentation Grade 
1- Mild 
2-Moderate 
3-Dense 
*reference No Pigmentation 
 
1.1 
1.1 
1
a 
 
(0.47, 2.57) 
(0.34, 3.26) 
0.98 
 
Phakic Status 
Phakic 
 
0.52 
 
(0.10, 2.67) 
 
0.44 
Hypertension(Y/N) 
No 
 
0.63 
 
(0.28, 1.43) 
 
0.27 
Diabetes Mellitus (Y/N) 
No 
 
1.07 
 
(0.30, 3.80) 
 
0.91 
Total Power 1
st
 SLT 
(mJ) 
1.01 (1.00, 1.03) 0.08* 
Total Number of shots 1
st
 SLT 
(shots) 
1.02 (0.96, 1.10) 0.41 
 
 
2 month IOP post treatment 
(mmHg) 
0.71 (0.61, 0.82) <0.001* 
 
Table 9: Univariable Selection Logistic Regression Analysis 
*Covariates that achieved p<0.10 in the initial variable selection logistic regression analyses were: total power of 1
st
 SLT 
(p=0.08) and age (p=0.09) 
a
model unable to converge due to insufficient data 
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Variable Odds Ratio 95% confidence 
Interval 
P-value 
Total Power 1
st
 SLT 
(mJ) 
1.02 (1.01, 1.04) 0.01 
 
*2 month IOP post 
treatment 
(mmHg) 
0.66 (0.57, 0.79) <0.001 
 
Table 10: Multivariable Logistic Regression Analysis Result of Baseline Factors 
* 2 month IOP is a post treatment predictor 
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Adverse Events during 
SLT 
Total Number of Events 
(n=20) 
Total Number of 
Patients reporting 
(N=19) (5.4%) 
Discomfort (Ocular 
and/or Headache) 
6 
 
6 (1.7%) 
IOP spike (>5mmHg) 6 6 (1.7%) 
Other (specify): 
Fewer shots 
Visualization of angle 
 
3 
5 
 
3 (0.9%) 
4 (1.1%) 
Adverse Events post 
SLT 
Total Number of Events 
Total (n=172) 
Total Number of 
Patients reporting 
(N=122) (34.4%) 
Discomfort (Ocular 
and/or Headache) 
92 82 (23.1%) 
Blurred/ altered vision 23 21 (5.9%) 
Change in Refraction 5 4 (1.1%) 
Inflammation post SLT 1 1 (0.3%) 
Other (specify): 
Photophobia 
Hyperaemia 
51 
21 
3 
47 (13.2%) 
20 (5.6%) 
3 (0.8%) 
 
Table 11: Summary of Laser related Adverse Events 
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Post-hoc analysis of clinical outcomes, predictors of success and safety of primary SLT used in treatment-naïve 
primary open-angle glaucoma (POAG) and ocular hypertension (OHT) patients 
